norelgestromin


Also found in: Wikipedia.

norelgestromin

A progestogen drug used in conjunction with ETHINYLOESTRADIOL (ethinylestradiol) as an oral or patch contraceptive.A brand name is Evra.
References in periodicals archive ?
25 mg SD not required AUC CYP3A4 Substrates Midazolam Cmax Adjustment 5 mg SD not required AUC Oral Contraceptive Ethinyl Estradiol Cmax Adjustment not required AUC Norelgestromin Cmax Adjustment not required AUC Lithium Ctrough Adjustment 600mg BID * not required
The primary objective was the pharmacokinetics of norgestimate, as determined by measuring the levels of its main metabolite, norelgestromin.
TABLE 3 A look at 4 generations of progestins (6) First generation Ethynodiol diacetate Norethindrone Second generation Levonorgestrel Norgestrel Third generation Desogestrel Etonogestrel * Gestodene ([dagger]) Norgestimate Norelgestromin ([double dagger]) Fourth generation Dienogest Drospirenone * Metabolite of desogestrel, contained in the vaginal ring and subdermal implant, ([dagger]) Currently not approved by the US Food and Drug Administration, but under review as a new patch.
The contraceptive Ortho Evra is a transdermal (through the skin) patch approved by the FDA in 2001 that contains ethinyl estradiol and the progesterone norelgestromin.
a review of combined contraceptives containing chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin and norgestimate
1) Concerns exist that drospirenone-containing combined oral contraceptives (OCs), the norelgestromin patch, and the etonogestrel vaginal ring may increase the risk of VTE, compared with second-generation OCs, although results from studies evaluating the thromboembolic risk of these products are conflicting.
This is a transdermal patch that delivers 20 [micro]g EE and 150 [micro]g norelgestromin daily.
Other newer methods include the contraceptive patch that delivers 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol per day and is replaced weekly for 3 weeks, followed by 1 week with no patch.
Ortho-Evra is marketed by Merck & Co and contains norelgestromin and ethinyl estradiol (EE).
The FDA officer reviewing the new drug application for Ortho Evra in 2001 noted that "there remains a definite clinical concern about the possibility of an increased risk of VTE events with Evra, containing norelgestromin, an NME [new molecular entity].
Ortho Evra is a weekly prescription patch that releases norelgestromin (a progestin hormone), and ethinyl estradiol (an estrogen hormone), through the skin into the blood stream to prevent pregnancy.
It stops ovulation by releasing the hormones norelgestromin and ethinyl estradiol into the bloodstream and is expected to be as effective as the traditional pill.